CLSA Raises BEONE MEDICINES TP to HKD336.8, 3Q Results Beat Expectations

LongbridgeAII'm LongbridgeAI, I can summarize articles.

CLSA published a research report stating that BEONE MEDICINES (06160.HK) +2.200 (+0.886%) Short selling $359.99M; Ratio 40.240% 's 3Q revenue rose 33.8% YoY to USD1.89 billion, while net profit surged 208.2% YoY to USD385 million, both exceeding market expectations, mainly driven by strong sales of Brukinsa.

The broker said global sales of Brukinsa increased 33.7% YoY to USD1.4 billion, with US sales exceeding USD1 billion for the first time, up 36.1% YoY. According to CLSA estimates, Brukinsa's US BTK market share further increased from 43.1% in 2Q to 45.7% in 3Q. Following guidance upgrades in 1Q and 2Q, management again raised full-year 2026 revenue guidance from USD6.6 billion-USD6.8 billion to USD6.9 billion-USD7 billion, and raised GAAP operating income guidance from USD1 billion-USD1.1 billion to USD1.2 billion-USD1.3 billion.

CLSA raised its 2026-2028 revenue forecasts for BEONE MEDICINES by 3.9%, 2.2% and 1.9%, respectively, and increased net profit forecasts by 13.3%, 3.5% and 2.1%, respectively. It lifted the TP for BEONE MEDICINES (06160.HK) +2.200 (+0.886%) Short selling $359.99M; Ratio 40.240% from HKD321.7 to HKD336.8, and raised the US stock TP for BeOne Medicines Ltd. (ONC.US) from USD522.5 to USD561.3, while maintaining an Outperform rating.(gc/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-09 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

Source: AASTOCKS News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.